Abstracts Archive - Page 1709 of 2607 - ACR Meeting Abstracts

Abstract Number: 1647 • 2016 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Staci Abramsky⁵, Min Wang⁵, Chudy Nduaka⁶, Ryan DeMasi⁵ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The objective of this analysis was to report tofacitinib safety and tolerability…
Abstract Number: 1648 • 2016 ACR/ARHP Annual Meeting
Long-Term Clinical, Radiographic and Patient-Reported Outcomes Based on RAPID3 Responses with Tofacitinib at 6 Months
Vibeke Strand¹, Martin J Bergman², Eun Bong Lee³, Yusuf Yazici⁴, Bethanie Wilkinson⁵, Liza Takiya⁶, Gene Wallenstein⁵, Chuanbo Zang⁷ and Eustratios Bananis⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Taylor Hospital, Ridley Park, PA, ³Seoul National University, Seoul, Korea, Republic of, ⁴New York University, Hospital of Joint Diseases, New York, NY, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. RAPID3 (Routine Assessment of Patient [Pt] Index Data 3) is a pooled…
Abstract Number: 1649 • 2016 ACR/ARHP Annual Meeting
Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients
Eugenio Chamizo Carmona¹, Carmen Carrasco-Cubero², Juan Jose Aznar Sánchez³, Raul Veroz Gonzalez³, Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez³ and Lara Chaves Chaparro¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Rheumatology, Complejo Universitario de Badajoz, Badajoz, Spain, ³Hospital de Mérida, Mérida, Spain
Background/Purpose: The aim of early RA treatment is remission. Intensive treatment with MTX and treat-to-target approach achieve remission in 30-50% patients. Modifiable risk factors, as…
Abstract Number: 1650 • 2016 ACR/ARHP Annual Meeting
Treatment with Tofacitinib Inhibits Human Naive B Lymphocyte Development and Function in Vitro
Jens Thiel¹, Nils Venhoff², Raquel Lorenzetti³, Bettina Bannert¹, Reinhard Voll⁴, Diego Kyburz⁵ and Marta Rizzi¹, ¹Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, Freiburg, Germany, ²Department of Internal Medicine, Clinic for Rheumatology and Clincal Immunology, Freiburg, Germany, ³Department of Internal Medicine, Clinic for Rheumatology and Clinical Immunology, 79106, Germany, ⁴Dpt. Rheumatology & Clinical Immunology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, University Medical Center, University of Freiburg, Freiburg, Germany, ⁵Department of Biomedicine, Experimental Rheumatology, University of Basel, 4051 Basel, Switzerland
Background/Purpose: B cells are pivotal to the pathogenesis of many autoimmune diseases including rheumatoid arthritis (RA). Tofacitinib, a JAK inhibitor, is effective and safe in…
Abstract Number: 1651 • 2016 ACR/ARHP Annual Meeting
A Case Series on Patients on Tofacitinib in Combination with a Biologic
Nashla Barroso¹ and Daniel E. Furst², ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although there have been significant advances in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). patients can experience a lack of or…
Abstract Number: 1652 • 2016 ACR/ARHP Annual Meeting
Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial
Natasja Stæhr Gudman¹, Pernille Juhl², Christian S. Thudium³, Anne Sofie Siebuhr⁴, Inger Byrjalsen⁵, Morten Asser Karsdal⁴ and Anne C. Bay-Jensen⁴, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Biomarkers & Research, Nordic Bioscience, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular disease, consequent to vascular and endothelial dysfunction, which…
Abstract Number: 1653 • 2016 ACR/ARHP Annual Meeting
Delineating the Effects of Rheumatoid Arthritis Pharmacotherapies on Vascular Inflammation: Rationale and Design of a Clinical Trial
Jon T. Giles¹, Katherine Liao², Nina Paynter³, Alyssa Wohlfahrt⁴, Afshin Zartoshti⁵, Rachel Broderick⁶, Daniel H. Solomon⁷ and Joan Bathon⁶, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ³Medicine, Harvard University, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, ⁶Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁷Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis is associated with an excess cardiovascular disease (CVD) burden. Fewer CVD events associated with specific DMARD therapies have been reported; however, causal…
Abstract Number: 1654 • 2016 ACR/ARHP Annual Meeting
Differential Serum Protein Expression in Groups of Psoriatic Arthritis Patients Characterised By Specific HLA Genotypes and Clinical Features
Musaab Elmamoun¹, Angela McArdle², Muhammad Haroon³, Robert Winchester⁴, Stephen R. Pennington⁵ and Oliver FitzGerald⁶, ¹Rheumatology, St. Vincent's University Hospital, Department of Rheumatology, Dublin 4, Ireland, ²University College Dublin, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁵UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland, ⁶St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with diverse clinical and radiographic manifestations. A number of human leukocyte antigen (HLA) alleles have been found…
Abstract Number: 1655 • 2016 ACR/ARHP Annual Meeting
Plasma microRNA Expression Profiles in Ankylosing Spondylitis Patients
Pilar Font-Ugalde¹, Carlos Perez-Sanchez¹, Chary Lopez-Pedrera¹, M. Carmen Castro-Villegas², Maria Carmen Abalos-Aguilera³, Patricia Ruiz-Limon³, Nuria Barbarroja¹, Ivan Arias de la Rosa³, Rafaela Ortega-Castro¹, Alejandro Escudero-Contreras³, Eduardo Collantes-Estévez¹ and Yolanda Jiménez-Gómez¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: MicroRNAs (miRNAs) are a group of single-stranded non-coding RNAs of 20-25 nucleotides in length that can potentially regulate every aspect of cellular function. Recent…
Abstract Number: 1656 • 2016 ACR/ARHP Annual Meeting
Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis
Yahui Grace Chiu¹, Edward Schwarz², Dongge Li³, Nelson Huertas³, Cristy Bell⁴, Debbie Campbell⁴ and Christopher T. Ritchlin⁵, ¹Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Orthopedeatrics, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow (BM) is not only the place where osteoclast precursors (OCPs) are derived from, but also the major reservoirs of OCPs. Current data…
Abstract Number: 1657 • 2016 ACR/ARHP Annual Meeting
Soluble Biomarkers May Differentiate Psoriatic Arthritis from Osteoarthritis
Vinod Chandran¹, Anthony V. Perruccio², Suzanne Li³, Fatima Abji⁴, Rajiv Gandhi⁵ and Dafna D Gladman⁶, ¹Medicine, Krembil Research Institute, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University Health Network, Arthritis Program, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: It is often difficult to differentiate psoriatic arthritis (PsA) from osteoarthritis (OA) in clinical practice. To aid clinical diagnosis, we aimed to identify soluble…
Abstract Number: 1658 • 2016 ACR/ARHP Annual Meeting
Regulatory Role of the IL-9/IL-9R System on Pannus Formation in Psoriatic Arthritis
Siba P. Raychaudhuri^1,2 and Smriti K. Raychaudhuri³, ¹Davis, CA, ²Rheumatology, Univ of California, Davis & VAMC Sacramento, Davis, CA, ³Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA
Background/Purpose: Earlier we have reported that synovial tissues of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are enriched with the Th9 cells along…
Abstract Number: 1659 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 1660 • 2016 ACR/ARHP Annual Meeting
Role of Immune System Cells and Induction of Netosis-Mediated Cell Death in the Development of Atherosclerosis in Ankylosing Spondylitis
Yolanda Jiménez-Gómez¹, Pilar Font-Ugalde¹, Patricia Ruiz-Limon², Maria Carmen Abalos-Aguilera², M. Carmen Castro-Villegas³, Nuria Barbarroja¹, Carlos Perez-Sanchez¹, Ivan Arias de la Rosa², Isabel Arias², Rafaela Ortega-Castro¹, Jerusalem Calvo-Gutierrez¹, Chary Lopez-Pedrera¹, Alejandro Escudero-Contreras² and Eduardo Collantes-Estévez¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain
Background/Purpose: Ankylosing Spondylitis (AS) is a chronic inflammatory disease associated with the development of atherosclerosis. Our aims were: 1) To evaluate the involvement of immune…
Abstract Number: 1661 • 2016 ACR/ARHP Annual Meeting
Toll-like Receptor 4 Induced IL-20 and IL-24 Stimulate Osteoblast Mineralization and Are Increased in Spondyloarthritis
Tue Wenzel Kragstrup^1,2, Morten Nørgaard Andersen³, Berit Schiøttz-Christensen⁴, Anne Grethe Jurik⁵, Malene Hvid⁶ and Bent Deleuran¹, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark, ⁴Hospital Lillebaelt, Middelfart, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: The pathogenesis of spondyloarthritis (SpA) involves activation of the innate immune system, inflammation and new bone formation. The innate immune system is activated through…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].